Previous 10 | Next 10 |
- BridgeBio completed an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), and a scientific advice engagement with the European Union (EU) European Medicines Agency (EMA) - FDA and EMA alignment was reached on the adequacy of a one-year, 2:1 randomized, placebo-co...
2023-08-30 16:08:00 ET Summary BridgeBio's shares have soared by over 150% since the positive results of its drug Acoramidis for treating ATTR-CM were released in July. The final data from the Phase 3 study of Acoramidis confirmed its positive results, and the company plans to sub...
- The primary endpoint was met (Win Ratio of 1.8) with a highly statistically significant p-value (p<0.0001); this primary endpoint result consistently favored acoramidis treatment across key subgroups, including across both variant and wild-type ATTR patients as well as across New Yo...
PALO ALTO, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, announced today that detailed Phase 3 results from ATTR...
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is the focus of IBN's latest stock spotlight. The company's shares have moved 3.2% on the day to $29.32. BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 ...
2023-08-15 11:40:24 ET Summary Generating high yields while taking on less market risk is possible. Our Advanced cash covered put selling strategy can generate high double-digit yields with being very conservative with risk. I believe that selling put options capitalizes on ma...
2023-08-14 07:00:00 ET Summary Biotech stocks faced challenges in the first half of the year, with the Nasdaq Biotechnology Index losing 3%, compared to strong advances in the broader market. The direction of the 10-year bond yield has become a key predictor of biotech industry pe...
2023-08-09 10:07:00 ET Wall Street can sometimes wax enthusiastic over young biotechs -- perhaps too much so. That may be the case right now with Palo Alto-based BridgeBio Pharma (NASDAQ: BBIO) , which analysts' consensus estimates predict will see its shares increase by 46% within ...
2023-08-03 10:24:48 ET BridgeBio Pharma press release ( NASDAQ: BBIO ): Q2 GAAP EPS of -$0.98. Revenue of $1.6M. For further details see: BridgeBio Pharma GAAP EPS of -$0.98, revenue of $1.6M
- Announced consistently positive results from the Phase 3 ATTRibute-CM study of acoramidis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM), including a highly statistically significant result observed on the primary endpoint with a Win Ratio of 1.8 (p<0.0001) and clinically me...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- BridgeBio has surpassed its interim analysis enrollment target for its Phase 3 FORTIFY study of BBP-418 in individuals living with LGMD2I/R9, with top-line results from the interim analysis expected in 2025 - Recent Type C interactions with U.S. Food and Drug Administration (FDA) focu...